Summary of Savara's Conference Call Company Overview - **Company**: Savara - **Focus**: Orphan rare pulmonary respiratory diseases - **Lead Candidate**: MOLBREEVI (molgramostim) under FDA review with a PDUFA date of August 22, 2023 [5][17] Disease Context - **Condition**: Autoimmune Pulmonary Alveolar Proteinosis (PAP) - **Characteristics**: Rare autoimmune disease affecting individuals globally, with no specific demographic predilection [5][10] - **Symptoms**: Shortness of breath, cough, fatigue, leading to significant morbidity and debilitation [10][11] - **Current Treatment**: Limited options including supportive care and a complex procedure called whole lung lavage, which is not standardized and requires significant resources [11][12] Mechanism of Action - **MOLBREEVI**: A recombinant GM-CSF inhaled once daily, designed to overcome autoantibodies that inhibit GM-CSF from activating macrophages [13][14] Clinical Data - **IMPALA2 Trial**: The largest and longest study in autoimmune PAP, enrolling 164 subjects in a 48-week double-blind placebo-controlled trial [17][18] - **Results**: - Primary endpoint (DLco) met at 24 weeks and maintained through 48 weeks, showing statistical significance [18][19] - Secondary endpoints (SGRQ total, SGRQ activity, exercise tolerance) also showed significant improvement [19][20] - **Publication**: Data published in The New England Journal of Medicine [21] Commercial Strategy - **Prevalence Estimates**: Diagnosed prevalence in the U.S. estimated at 15-16 per million, with a total of approximately 5,500 prevalent patients identified [37][39] - **Target Audience**: Approximately 1,700 key accounts and 4,000-5,000 pulmonologists targeted for outreach [44][46] - **Testing Initiatives**: Offering a no-cost dried blood spot card antibody test to aid in diagnosis [50][51] Regulatory and Financial Position - **BLA Submission**: Recently accepted by the FDA with priority review granted; no Advisory Committee required [28] - **Cash Position**: $264 million on the balance sheet, with additional non-dilutive capital available upon FDA approval [58] - **Pricing Strategy**: Expected pricing range of $400,000-$500,000 per patient per year, with positive feedback from payers regarding budget impact [57] Launch Preparations - **Sales Force**: Approximately 27 representatives planned to target the market effectively [59] - **International Strategy**: Plans to file for MAA in Europe and the U.K., with intentions to maintain full control of the asset [55][56] Key Takeaways - Savara is positioned to address a significant unmet need in the treatment of autoimmune PAP with MOLBREEVI, supported by robust clinical data and a strategic commercial plan [5][17][57] - The company is actively preparing for a potential launch in August 2023, with a focus on patient identification and education within the pulmonology community [50][55]